DailyIQ
Last updatedUpdating…

IQV·IQVIA Holdings Inc.

$262.16
+1.48 (+0.57%)
After Hours
High
$266.66
Open
$264.37
Market Cap
43.04B
52W High
$277.40
Low
$260.81
P. Close
$262.16
P/E
31.30
52W Low
$149.01
Fwd P/E
18.06
DailyIQ Est.
$306.26
Inst. Ownership
50.4%
Short Interest
1.95%
Days to Cover
1.7
NewEarnings release, scored · filed Jul 28, 2026Guidance raised · tone +10.4 vs prior release · 48 lines scoredSee the breakdown
Technical Score (1D)
74
BULLISH
News Sentiment
79
BULLISH
On Oct 13, IQVIA announced it would integrate Veeva Applications into its clinical development studies. The integration was intended to streamline data capture, improve regulatory compliance, and accelerate trial timelines. By leveraging Veeva’s cloud‑based platform, IQVIA expected to enhance collaboration across its global research network. The decision reflected the company’s ongoing investment in digital tools to maintain a competitive edge in the life‑science services market.
LOW TARGET
$250 -4.6%
2 analysts
MEAN TARGET
$296 +13.2%
12 analysts
HIGH TARGET
$345 +31.7%
16 analysts
PRICE RANGE
$250.00 - $345.00
SB / B / H / S / SS
9/14/5/1/1
DAILYIQ EST.
$306.26 (+16.9%)
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NYQ
Country
United States
Website
Symbol
IQV
Description
IQVIA Holdings, Inc. is a global provider of technology, analytics, and services to the life sciences and healthcare industries. The company's core value proposition lies in its ability to offer comprehensive solutions across the drug development and commercialization lifecycle. IQVIA operates through three primary segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, each contributing to its integrated offerings. These solutions help clients with clinical trial support, data-driven insights for healthcare decision-making, and commercialization strategies. Serving pharmaceutical, biotechnology, and medical device companies, IQVIA is strategically positioned to support the evolving needs of the healthcare sector.
Bought (1Y)
0 shares
$0
Sold (1Y)
121,860 shares
$29.9M
Berkshire James G.See Remarks
Option Exercise5,381 shares2026-09-02
Berkshire James G.See Remarks
D2,713 shares2026-09-02
Berkshire James G.See Remarks
Sell2,668 shares2026-09-02
Berkshire James G.See Remarks
Option Exercise5,381 shares2026-09-02
STAUB W RICHARDSee Remarks
Sell5,500 shares2026-08-03
66/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
8.3%
Revenue CAGR
9.9%
Current Ratio
0.75x
Debt / Equity
2.42x
Return on Equity
20.9%
Earnings Summary
IQVIA Holdings, Inc. is a global provider of technology, analytics, and services to the life sciences and healthcare industries, delivering integrated solutions across drug development, commercialization, and clinical trial support. Operating within the diagnostics and research sector, the company leverages data‑driven insights to help pharmaceutical, biotechnology, and medical device clients optimize decision‑making and market performance. In the most recent quarter, Q2 2026, IQVIA reported diluted earnings per share of $3.15, slightly below the $3.24469 estimate, while revenue of $4.368 billion surpassed the $4.344 billion forecast, marking a 1.4% YoY increase from Q2 2025’s $4.017 billion. Compared to the prior two quarters, EPS growth slowed from $2.81 in Q3 2025 to $3.15 in Q2 2026, and revenue accelerated from $4.100 billion to $4.368 billion, indicating a modest earnings deceleration amid stronger top‑line momentum. Historically, IQVIA has consistently outperformed consensus estimates in the last four quarters, with EPS beats in each period and revenue growth maintained even when EPS missed guidance, reflecting a resilient revenue base. The company’s YoY growth trajectory has been upward, with revenue rising from $3.958 billion in Q4 2024 to $4.368 billion in Q2 2026, while EPS has trended upward from $3.12 in Q4 2024 to $3.15 in Q2 2026, albeit with occasional guidance misses. Recent news highlights the launch of Life Science Models and IQVIA Explorer at TechIQ 2026, showcasing new data‑driven platforms that promise to reduce analysis time and enhance clinical trial predictions, potentially supporting future revenue expansion.

EPS

EstBeatMiss
$2.54$2.74$2.95$3.16$3.37Q1'25Q2'25Q3'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.27 - -
Q2'26$3.24$3.15-2.9%
Q1'26$3.04$2.90-4.7%
Q3'25$2.98$3.00+0.8%
Q2'25$2.77$2.81+1.4%
Q1'25$2.63$2.70+2.6%

Revenue

EstBeatMiss
$3.7B$3.9B$4.1B$4.3B$4.5BQ1'25Q2'25Q3'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$4.4B - -
Q2'26$4.3B$4.4B+0.5%
Q1'26$4.2B$4.2B-2.3%
Q3'25 - $4.1B -
Q2'25 - $4.0B -
Q1'25 - $3.8B -

Market Data

IQV Stock Snapshot

BULLISH74/100
$262.01−$0.15 (0.1%)
Market cap
43.04B
P/E ratio
31.3
Day range
$260.81 – $266.66
News sentiment
79/100 · Bullish
Analyst target
$296.47 (+13.2%)
Consensus
Buy · 30 analysts
52-week range+75.8% off low · -5.5% from high
$149.01$277.40
Price $262.01 DailyIQ Est. $306.26

Price is near its 52-week high, and the momentum read backs that positioning up. In Healthcare, names this size usually take direction from sector flows before company-level news.

Reverse DCF

What growth is priced into IQV?

CHEAP

At today's price, IQVIA Holdings Inc. needs to grow free cash flow about 13.1% a year for the next 10 years to justify its valuation at a 8.14% cost of capital. Over its actual history it has compounded free cash flow at 22.0% a year, so the market is asking for 8.9 percentage points below its own delivered rate. On that basis IQV looks priced below what its own growth record supports.

Implied FCF growth
13.1%
Historical FCF CAGR
22.0%
Growth gap
-8.9 pts
Verdict
CHEAP
Discount rate (WACC)
8.14%
Beta
0.89

Behaviour On Record

What IQV's own history says about today's numbers

Realized volatility (21d)
22.2% 42nd pct
Below its peak
-7.3%
vs 200-day average
+26.4%
Up days (1y)
52%

IQVIA Holdings Inc. is currently running 22.2% annualised volatility over the last 21 sessions. Measured against IQV's own 13 years of daily returns rather than a market-wide average, that is the 42nd percentile — close to its own typical level, against a typical reading of 24.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

IQV is trading -7.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -20.0%, and the deepest was -49.4% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +26.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 97th percentile — a wider gap than this stock usually carries. Over the past year IQV closed higher on 52% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 14 years of records, IQV finished the month higher 6 of 14 times, with a median return of -0.1% and an average of +0.2%. Its strongest month historically has been July at +9.5% on average, its weakest September at -3.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: IQV has opened more than 2% away from the prior close in 129 of 3,268 sessions (3.9% of the time), with the largest gaps running +7.6% and -16.5%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against IQV's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of IQV's sector?

IQVIA Holdings Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for IQV?

CallsPuts

For IQVIA Holdings Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is roughly balanced between puts and calls (put/call ratio of 0.87), with at-the-money implied volatility around 39.3%. The options market is pricing roughly a ±2.8% move by that expiry — a range of about $254.06–$268.66.

Put/call ratio (2026-10-16)
0.87
ATM implied volatility
39.3%
Total open interest
3,250
Expected move by 2026-10-16
±2.8% ($254.06–$268.66)

Analyst Rating Changes

Are analysts turning bullish or bearish on IQV?

Stifel most recently reiterated its rating on IQVIA Holdings Inc. to Buy on Oct 14, 2026 with a price target of $303 (from $276). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Stifel — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 14, 2026StifelMaintainedBuy$276 → $303
Oct 7, 2026MizuhoMaintainedOutperform$275 → $300
Oct 7, 2026BarclaysMaintainedOverweight$275 → $300
Sep 29, 2026RBC CapitalMaintainedOutperform$247 → $319
Sep 28, 2026Truist SecuritiesReiteratedBuy$300 → $329
Sep 17, 2026Morgan StanleyMaintainedEqual-Weight$240 → $270
Jul 29, 2026JP MorganMaintainedOverweight$225 → $285
Jul 29, 2026StifelMaintainedBuy$220 → $276
Jul 29, 2026TD CowenMaintainedBuy$233 → $288
Jul 29, 2026RBC CapitalMaintainedOutperform$221 → $247
Jul 29, 2026BMO CapitalMaintainedOutperform$210 → $270
Jul 29, 2026BairdMaintainedOutperform$252 → $287

Earnings Release, Scored

What did IQVIA Holdings Inc.'s latest earnings release say?

Filed Jul 28, 2026 · SEC Form 8-K, Exhibit 99

Guidance raised
Tone84.2/ 100+10.4 vs prior release
Hedging words1.09per 100 words+0.16 vs prior release
Tone, last 2 releasesScale 50–90

Most important lines

  1. 1

    To reflect stronger organic revenue growth, and changes in the M&A and foreign exchange impacts, the company is raising its full-year 2026 guidance for revenue to be between $17,275 million and $17,475 million, for Adjusted EBITDA to be between $4,000 million and $4,050 million and for Adjusted Diluted Earnings per Share to be between $12.80 and $13.00.

    Guidance raised
  2. 2

    The new mid-point of the revenue growth guidance is 6.5% versus the prior guidance of 5.8%, reflecting approximately 100 basis points higher organic revenue growth, and approximately 50 basis points higher contribution from M&A offset by approximately 80 basis points unfavorable change in foreign exchange impact, all versus prior guidance.

    Guidance raisedNew this quarter
  3. 3

    Revenue $4,368 million, up 8.7% year-over-year

    New this quarter

Peers & ETF holders

IQV peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

79/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
On October 13, IQVIA announced it would integrate Veeva Applications into its clinical development studies. The move aims to streamline data capture, improve regulatory compliance, and accelerate trial timelines. By leveraging Veeva’s cloud-based platform, IQVIA expects to enhance collaboration across its global research network. The decision reflects the company’s ongoing investment in digital tools to maintain a competitive edge in the life‑science services market.
What did this article say?
IQVIA announced on Oct 13 that it would adopt Veeva Systems’ Clinical Operations Applications to enhance its clinical trial management capabilities. The partnership aims to streamline data capture, improve regulatory compliance, and accelerate time‑to‑market for IQVIA’s clients. While the move strengthens IQVIA’s product suite, it is a routine expansion rather than a market‑disrupting event. The decision is expected to modestly support IQVIA’s service offering without materially altering its financial outlook.
What did this article say?
IQVIA Holdings prepared to report its third‑quarter earnings on October 9, with analysts forecasting a high‑single‑digit increase in earnings per share. The company’s guidance suggests continued revenue momentum and operational efficiency. This positive outlook reflects confidence in IQVIA’s data‑analytics and clinical trial services amid a stable market environment.
What did this article say?
On Oct 8, Leerink Partners increased its price target for IQVIA Holdings from $280 to $310, signaling a bullish assessment of the company’s future prospects. The upgrade reflects expectations of stronger earnings growth and improved market positioning. The move may enhance investor confidence and influence market sentiment toward the stock.
What did this article say?
IQVIA announced the launch of its Life Science Models at TechIQ 2026, a suite designed to predict clinical trial outcomes for life sciences companies. The models integrate proprietary expert content, domain knowledge, and regulatory frameworks with advanced technologies such as NVIDIA Nemotron and AWS infrastructure. By linking molecular and treatment data to patient journeys and clinical outcomes, the platform aims to improve trial design and reduce uncertainty. The introduction signals IQVIA’s continued investment in data‑driven solutions for the pharmaceutical sector.
What did this article say?
IQVIA announced the launch of IQVIA Explorer, a platform that integrates data, analytics, and workflows to provide near‑real‑time commercial intelligence for life sciences and healthcare companies. The tool promises to reduce analysis time from weeks to minutes, enabling teams to assess treatment patterns, resource allocation, and new assumptions more efficiently. The launch was showcased at TechIQ 2026, positioning IQVIA as a leader in commercial analytics solutions.
What did this article say?
Mizuho analyst Ann Hynes maintained an Outperform rating for IQVIA Holdings and increased the price target from $275 to $300. The upgrade reflects confidence in the company’s earnings outlook and growth prospects. The higher target suggests a bullish view on IQVIA’s future performance.
What did this article say?
Mizuho Securities lifted its price target for IQVIA Holdings (IQV) to $300 from $275, reflecting a more optimistic view of the company's prospects. The upgrade follows a broader assessment of IQVIA’s business model and growth potential in the healthcare data analytics sector. Analysts noted that the new target aligns with a bullish stance on the firm’s earnings trajectory and market position. The adjustment signals confidence in IQVIA’s ability to generate incremental revenue and improve profitability in the coming years.
What did this article say?
Barclays analyst Luke Sergott upgraded IQVIA Holdings to an Overweight rating on October 7, 2024. The firm increased its price target from $275 to $300, citing confidence in the company’s growth prospects. The upgrade signals a positive outlook for investors and reflects Barclays’ belief in IQV’s ability to deliver value. The move is expected to influence market sentiment and could support the stock’s performance.

Technical Analysis

Real-time indicators across multiple timeframes

74
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $16.56B combined position · 14 adding, 11 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy19,650,53211.90%$4.43B2026-01-29
BlackRock, Inc.▼ Sell14,549,6938.81%$2.81B2026-08-07
Harris Associates L P▲ Buy12,183,8307.38%$2.35B2026-08-14
JPMorgan Chase & Co▲ Buy6,139,7753.72%$1.19B2026-08-12
Artisan Partners Limited Partnership▼ Sell4,743,4342.87%$916.53M2026-08-13
Geode Capital Management, LLC▼ Sell4,454,1342.70%$857.16M2026-08-12
Invesco Ltd.▲ Buy3,275,1411.98%$632.82M2026-08-14
Morgan Stanley▲ Buy2,707,2521.64%$523.10M2026-08-13
Norges Bank▲ Buy2,264,9441.37%$437.63M2026-08-12
Goldman Sachs Group Inc▲ Buy1,949,7971.18%$376.74M2026-08-14
Northern Trust Corp▼ Sell1,709,1611.04%$330.24M2026-08-13
AQR Capital Management LLC▲ Buy1,536,8740.93%$296.95M2026-08-14
AllianceBernstein L.P.▼ Sell1,643,1021.00%$280.21M2026-08-14
Bank of America Corp▼ Sell1,219,0810.74%$235.55M2026-08-14
FMR LLC (Fidelity)▼ Sell1,212,6700.73%$234.31M2026-08-13
Balyasny Asset Management L.P.▲ Buy700,4250.42%$135.34M2026-08-14
Millennium Management LLC▲ Buy516,7240.31%$99.84M2026-08-14
D. E. Shaw & Co., Inc.▲ Buy466,2340.28%$90.09M2026-08-14
Capital World Investors▼ Sell316,8870.19%$61.23M2026-08-12
Man Group plc▲ Buy295,6790.18%$57.13M2026-08-14
Point72 Asset Management, L.P.▲ Buy279,4680.17%$54.00M2026-08-14
Wells Fargo & Company▼ Sell229,3910.14%$44.32M2026-08-14
Citadel Advisors LLC▼ Sell229,3660.14%$44.32M2026-09-02
Citigroup Inc▼ Sell222,5030.13%$42.99M2026-08-03
Gotham Asset Management, LLC▲ Buy140,6920.09%$27.18M2026-08-14
Q2 2026 flow:3.92M sh bought ($757.19M)3.52M sh sold ($653.00M)net +393.9K sh (+$104.18M)
Congressional Trading Activity
11 disclosed trades · ~$204.0K est. traded value · 1 buys, 10 sells
MemberChamberStateTypeAmountTradedFiled
Kevin HernHouseOK01▼ Sell$15K - $50K2026-09-142026-09-25
Kevin HernHouseOK01▼ Sell$1K - $15K2026-09-082026-09-25
Kevin HernHouseOK01▼ Sell$1K - $15K2026-09-032026-09-25
Kevin HernHouseOK01▼ Sell$50K - $100K2026-03-162026-04-03
John BoozmanSenateAR▼ Sell$1K - $15K2025-10-022025-11-15
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-05-152025-05-31
Rob BresnahanHousePA08▲ Buy$15K - $50K2025-04-082025-05-08
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-02-252025-03-27
John F. ReedSenateRI▼ Sell$1K - $15K2019-02-282019-03-18
John F. ReedSenateRI▼ Sell$1K - $15K2019-02-042019-03-01
John F. ReedSenateRI▼ Sell$1K - $15K2018-03-092018-03-12